Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model

Journal of Controlled Release : Official Journal of the Controlled Release Society
Bonnie L HylanderElizabeth A Repasky

Abstract

Interstitial fluid pressure (IFP) is elevated in tumors and high IFP, a negative cancer prognosticator, is known to limit the uptake and efficacy of anti-tumor therapeutics. Approaches that alter the tumor microenvironment and enhance uptake of therapeutics are collectively referred to as tumor "priming". Here we show that the cytotoxic biological therapy Apo2L/TRAIL can prime the tumor microenvironment and significantly lower IFP in three different human tumor xenograft models (Colo205, MiaPaca-2 and a patient gastrointestinal adenocarcinoma tumor xenograft). We found that a single dose of Apo2L/TRAIL resulted in a wave of apoptosis which reached a maximum at 8h post-treatment. Apoptotic debris subsequently disappeared concurrent with an increase in macrophage infiltration. By 24h post-treatment, treated tumors appeared less condensed with widening of the stromal areas which increased at 48 and 72h. Analysis of tumor vasculature demonstrated a significant increase in overall vessel size at 48 and 72h although the number of vessels did not change. Notably, IFP was significantly reduced in these tumors by 48h after Apo2L/TRAIL treatment. Administration of gemcitabine at this time resulted in increased tumor uptake of both gemcit...Continue Reading

References

Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·P A NettiR K Jain
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Feb 20, 2004·Nature·Timothy P PaderaRakesh K Jain
Oct 29, 2004·Nature Reviews. Cancer·Carl-Henrik HeldinArne Ostman
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alphonse G TaghianSimon N Powell
Jul 25, 2006·Nature Reviews. Cancer·Andrew I Minchinton, Ian F Tannock
Apr 11, 2007·The Journal of Pharmacology and Experimental Therapeutics·Dan LuJessie L-S Au
Jun 15, 2007·Microvascular Research·Dai Fukumura, Rakesh K Jain
Oct 24, 2007·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Yan XuElizabeth A Repasky
Jun 5, 2008·The Journal of Clinical Investigation·Avi Ashkenazi, Roy S Herbst
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Avi AshkenaziS Gail Eckhardt
Oct 16, 2008·Anti-cancer Agents in Medicinal Chemistry·Jean-Philippe Cosse, Carine Michiels
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid S Mendelson
Sep 15, 2010·Nature Reviews. Clinical Oncology·Rakesh K Jain, Triantafyllos Stylianopoulos
Oct 28, 2010·Molecular Cancer Therapeutics·Curtis B ThompsonGregory I Frost
Jan 12, 2011·Cancer Letters·Pamela M Holland
Jan 26, 2011·Cancer Biology & Therapy·Hope M AmmDonald J Buchsbaum
Apr 7, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nadine Rohwer, Thorsten Cramer
Jun 2, 2011·Nature Reviews. Drug Discovery·Peter Carmeliet, Rakesh K Jain
Jul 5, 2011·Biomaterials·Shenglin LuoChunmeng Shi
Jul 12, 2011·Physiological Reviews·Shom GoelRakesh K Jain
Oct 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Charles SoriaFiona Blackhall
Aug 31, 2012·Proceedings of the National Academy of Sciences of the United States of America·Triantafyllos StylianopoulosRakesh K Jain
Nov 2, 2012·The Journal of Pharmacology and Experimental Therapeutics·Sihem Ait-OudhiaDonald E Mager
May 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rakesh K Jain
Jun 21, 2014·Cell Death and Differentiation·J LemkeH Walczak
Dec 21, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Iftikhar Ali KhawarHyo-Jeong Kuh

❮ Previous
Next ❯

Citations

Mar 17, 2016·Expert Opinion on Drug Delivery·Beth GoinsAnde Bao
Jun 6, 2016·Seminars in Cancer Biology·Marc Diederich, Claudia Cerella
May 26, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Charlotte CarlierWim Ceelen
Dec 1, 2017·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Stephanie J Blocker, Anthony F Shields
Nov 11, 2017·Nature Reviews. Cancer·Mark W Dewhirst, Timothy W Secomb
Nov 16, 2018·Frontiers in Pharmacology·Clara FernandesMayur C Yergeri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.